Characterisation of a Novel Series of Aprotinin-Derived Anticoagulants

Summary

Previous investigations have indicated that interference with the initial level of the blood coagulation may lead to effective antithrombotic therapy. Recently a series of potential coagulation inhibitors derived from bovine pancreatic trypsin inhibitor (BPTI, aprotinin) was described. We have determined their inhibition constants, effects on coagulation assays, effects in an in vitro human thrombosis model and pharmacological profiles in hamsters. The aprotinin-derived analogues (4C2,7L22, 5L15, 6L15, 5L84) showed significantly increased inhibitory activity towards factor Xa, factor Vlla-tissue factor (TF) complex, factor XIa and plasma kallikrein or a combination of them, and a significantly decreased plasmin inhibition as compared to aprotinin. In the coagulation assays, 4C2 and 7L22 mainly inhibited factor Xa, 5L15 and 6L15 inhibited factor VIIa-TF complex and 5L84 inhibited factor Xa, factor VIIa-TF complex and the contact activation. In flow chamber experiments with human blood 7L22, 5L15, 6L15, 5L84 and rTAP significantly inhibited fibrin formation and platelet deposition on extracellular matrix from phorbol ester stimulated human endothelial cells both under high and low shear stress and in the presence of low molecular weight heparin. The pharmacological profiles of the aprotinin analogues and rTAP with a mean residence time of 64 to 140 min were not significantly different. Modification of an aprotinin analogue with PEG (5L15-PEG) resulted in a 10-fold decrease of the inhibition constant for the factor VIIa-TF complex and in a significant prolongation of the secondary half-life, while the initial half-life was unchanged.

Thus the investigated aprotinin-derived coagulation inhibitors resulted in a series of combined coagulation inhibitors with a pharmacological behaviour, which justifies in vivo testing of their potential antithrombotic action, as reported in the accompanying paper.

• References

• 1 Bach RR. Initiation of coagulation hy tissue factor. CRC Clit Rev Bioeliem 1988; 23: 339-368
• 2 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis Am J Pathol 1989; 134: 1087-1097
• 3 Scully MF. Kinetic considerations on the physiologic control of thrombin and factor Xa. Semin Tliromb Hcmost 1992; 18: 218-223
• 4 Zwaal RF A. Membrane and lipid involvement in blood coagulation. Biochim Biophys Acta 1978; 515: 163-205
• 5 Mann KG, Ncshcim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16
• 6 Broze GJ. Tissue factor pathway inhibitor and the revised hypothesis of blood coagulation. Trends Cardiovasc Med 1992; 2: 72-77
• 7 Zwaal RF A, Bevers EM, Comfurius P. Platelets and coagulation. In: Blood Coagulation. Zwaal RB A, Hemker HC. eds New York: Blsevicr Science Publishers; 1986: 141-169
• 8 Mann KG, Nesheim ME, Fraey PB. Non enzymatic cofactors: Factor V. In: Blood Coagulation. Zwaal RF A, Hemker HC. eds New York:: Elsevier Science Publishers; 1993: 15-32
• 9 Lankiewicz MW, Bell WR. A unique circulating inhibitor with specificity for coagulation factor X. Am J Med 1992; 93: 343-346
• 10 Hirsh J. Heparin and low-molecular weight heparins. Cor Art Dis 1992; 3: 990-1002
• 11 Théroux P, Latour JP. Anticoagulants and their use in acute ischemic syndrome. In: Textbook of interventional cardiology. Topol EJ. ed Philadelphia: W. B. Saunders Company; 1990: 24-48
• 12 Neeper MP, Waxman L, Smith DE, Schulman CA, Sardana M, Ellis RW, Schaffer LW, Siegl PK, Vlasuk GP. Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa J Biol Chem 1990; 265: 17746-1752
• 13 Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993; 70: 212-216
• 14 Eisenberg PR. Development of novel anticoagulants for use as conjunctive therapy for thrombolysis. Cor Art Dis 1992; 3: 1010-1015
• 15 Schaffer LW, Davidson JT, Vlasuk GP, Siegl PK. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis Circulation 1991; 84: 1741-1748
• 16 Imura Y, Stassen JM, Collen D. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. J Pharmacol Exp Ther 1992; 261: 895-898
• 17 Zoldhelyi P, Fuster V, Chesebro JH. Antithrombins as conjunctive therapy in arterial thrombolysis. Cor Art Dis 1992; 3: 1003-1009
• 18 Beretz A, Cazenave JP. Old and new natural products as the source of modern antithrombotic drugs. Planta Med 1991; 57 S 68-72
• 19 Jacobs JW, Cupp EW, Sardana M, Friedman PA. Isolation and characterization of a coagulation factor Xa inhibitor from black fly salivary glands. Thromb Haemost 1990; 64: 235-238
• 20 Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis Circulation 1992; 85: 805-815
• 21 Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J. et.al Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622-1629
• 22 Zoldhelyi P, Webster MW, Fuster V, Grill DE, Gaspar D, Edwards SJ, Cabot CF, Chesebro JH. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters Circulation 1993; 88: 2015-2022
• 23 Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236-261
• 24 Hardy JF, Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. Can J Cardiol 1992; 39: 353-365
• 25 De Maeyer M, Lambeir AM, Laroche Y, Lasters I, Lauwereys M, Mathys-sens G, Stanssens P, Ripka W, Vlasuk G. Recombinant Kiinitz inhibitors of coagulation proteases. I Site specific mutagenesis Thromb Haemost 1993; 69: 888 (abstract 1245)
• 26 De Maeyer M, Lambeir AM, Laroche Y, Lasters I, Lauwereys M, Mathyssens G, Stanssens P, Ripka W, Vlasuk G. Recombinant Kiinitz inhibitors of coagulation proteases. II Random mutagenesis Thromb Haemost 1993; 69: 889 (abstract 1250)
• 27 Stanssens P, De Maeyer M, Lambeir AM, Laroche Y, Lauwereys M, Lasters I, Ripka WC. Design of inhibitors of serine proteases: Use of site selective and random mutagenesis to define the pharmacophore and conformational selectivity of Kunitz inhibitors towards factors Xa and VIIa. Submitted.
• 28 Zawilska K, Zozulinska M, Turowiecka Z, Blahut M, Drobnik L, Vinazzer H. The effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits. Thromb Res 1993; 69: 315-320
• 29 Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VUI-von Willebrand factor bound to subendothelium. Nature 1978; 279: 636-638
• 30 Zwaginga JJ, Sixma JJ, de Groot PG. Activation of endothelial cells induces platelet thrombus formation on their matrix. Studies of new in vitro thrombosis model with low molecular weight heparin as anticoagulant Arteriosclerosis 1990; 10: 49-61
• 31 Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation. Blood 1991; 78: 423-434
• 32 Laroche Y, Strome V, De Meutter J, Messens J, Lauwereys M. High-level secretion and very efficient isotopic labeling of tick anticoagulant peptide (TAP) expressed in the methylotrophic yeast, Pischia pastoris. Bio/Technology 1994; 11: 1119-1124
• 33 Roberts BL, Markland W, Ley AC, Kent RB, White DW, Guterman SK, Ladner RC. Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage. Proc Natl Acad Sci USA 1992; 89: 2429-33
• 34 Jordan SP, Waxman L, Smith DE, Vlasuk GP. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry 1990; 29: 11095-11100
• 35 Sakariassen KS, Aarts PA, de Groot PG, Houdijk WP, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983; 102: 522-535
• 36 Lozano M, Bos A, de Groot PG, van Willigen G, Meuleman DG, Ordinas A, Sixma JJ. Suitability of low molecular-weight heparin(oid)s and a pentasaccharide for an in vitro human thrombosis model. Arterioscl and Thromb 1994; 14: 1215-1222
• 37 Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker Inc; 1983
• 38 Labaune JP. Handbook of pharmacokinetics. Toxicity assessment of chemicals In: Ellis Horwood series in pharmaceutical technology. Rubinstein MH. ed Chichester, UK:: Ellis Horwood Ltd; 1989: 293-316
• 39 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-1084
• 40 Pintigny D, Dachary Prigent J. Aprotinin can inhibit the proteolytic activity of thrombin A fluorescence and an enzymatic study. Eur J Biochem 1992; 207: 289
• 41 Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-1896
• 42 Lindhout T, Blezer R, Schoen P, Nordfang O, Reutelingsperger C, Hemker HC. Activation of factor X and its regulation by tissue factor pathway inhibitor in small-diameter capillaries lined with human endothelial cells. Blood 1992; 79: 2909-2916
• 43 Grabowski EF, Zuckerman DB, Nemerson Y. The functional expression of tissue factor by fibroblasts and endothelial cells under flow conditions. Blood 1993; 81: 3265-3270
• 44 Alkhamis TM, Beissinger RL, Chediak JR. Effect of hirudin on platelet deposition to an artificial surface during low-stress shear flow of whole blood. Biomaterials 1993; 14: 865-870
• 45 Van den Besselaar AM H P, Dirven R, Bertina RM. Tissue factor-induced coagulation can be inhibited by aprotinin (Trasylol). Thromb Haemost 1993; 69: 298
• 46 Spannagl M, Dietrich W, Beck A, Schramm W. High dose aprotinin reduces prothrombin and fibrinogen conversion in patients undergoing extracorporeal circulation for myocardial revascularization. Thromb Haemost 1994; 72: 159-160
• 47 Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor Jr FB, Colman RW. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons J Clin Invest 1993; 91: 61-68
• 48 Smith RP, Higuchi DA, Broze GJ. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990; 248: 1126-1128
• 49 Stassen JM, Lambeir AM, Vreys I, Deckmyn H, Mathyssens G, Nystrom A, Vermylen J. Characterization of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo Thromb Haemost 1995; 74: 655-659